Volume 23, Issue 98 And 3 (5-2015)                   J Adv Med Biomed Res 2015, 23(98 And 3): 29-40 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Daryanoosh F, Aminilari Z. The effect of 12 weeks of resistance training on the Apelin, Omentin-1 levels and insulin resistance in the elderly overweight women with type 2 diabetes. J Adv Med Biomed Res 2015; 23 (98 and 3) :29-40
URL: http://journal.zums.ac.ir/article-1-3140-en.html
1- Dept. of Sport Physiology, School of Physical Education and Sport Sciences, Shiraz University, Shiraz, Iran , aminimahboob@yahoo.com
2- Dept. of Sport Physiology, School of Physical Education and Sport Sciences, Shiraz University, Shiraz, Iran
Abstract:   (160896 Views)

Background and Objective: Nowadays, it has been recognized that Apelin and Omentin as the hormones secreted by adipose tissue, can be effective in regulating metabolism. The purpose of the present study was to determine the impact of 12 weeks of resistance training exercises on the Apelin, Omentin-1 levels and insulin resistance in overweight elderly women suffering from type 2 diabetes. Materials and Methods: 30 elderly obese women were selected then assigned into two groups of control (n=15) and case (n=15) based on their body fat percentage and BMI. The mean age and BMI of the participants in the case and control groups were 53.30 ± 5.88, 28.7±2/2 and 51.26± 7.12 , 29.11 ± 3.6 respectively. The intervention program included resistance exercises with 50-55% 1 RM conducted increasingly, 3 times a week for 12 weeks. Blood samples were taken before the training and 24 hours after the last training session. U Mann-Whitney Test was used to analyze the data and Wilcoxon test was used at the significance level of p≤ 0/05 to compare pretest and posttest results in the groups, Results: The results showed that there was a significant difference in glucose level (p<0.00001), but no significant difference was found between Apelin and Omentin-1 levels and insulin resistance. Conclusion: It is concluded that although our training exercise program changed the glucose metabolism, it cannot be considered as a potential means of evoking the level of Apelin and Omentin-1. This may be due to inadequate time and intensity of the training exercises. References 1- Larsen L, Akerstrom T, Nielsen S, Keller P, Keller C, Pedersen BK. Visfatin mRNA expression in human subcutaneous adipose ttissue is regulated by exercise. Am J Physiol Endocrinol Metab. 2007 292: E24-E31. 2- Nikbakht H, Taghyan F, Karbasian A. The effect of aerobic training on apelin levels in obese women. Research on Sport Sciences. 2004 11: 45-58. [Full Text in Persian] 3- Heinonen MV, Purhonen AK, Miettinen P, et al. Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding. Regul Pept. 2005 130: 7-13. 4- Kleinz MJ, Skepper JN, Davenport AP. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept. 2005 126: 233-240. 5- Ishida J, Hashimoto T, Hashimoto Y, et al. Regulatory roles for APJ, A seventransmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem. 2004 279: 26274-79. 6- Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004 89: 2548-56. 7- Yanovski JA, Yanovski SZ. Recent advances in basic obesity research. JAMA. 1999 282: 1504-6. 8- Schaffler A, Neumeier M, Herfarth H, Furst A, Scholmerich J, Buchler C. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta. 2005 1732: 96-102. 9- De Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ. Omentin plasma levels and gene expression are decreased in obesity. Diabetes. 2007 56: 1655-61. 10- Tan BK, Adya R, Farhatullah S, et al. Omentin-1, a novel adipokine, is decreased overweight insulinresistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes. 2008 57: 801-8. 11- Larijani B,Ghodsi M.Leptin. A new adypocyte hormone and its role in the obesity. Iranian Journal of Diabetes and Lipid Disorders. 2005 4: 1-10. (Farsi) 12- Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA. 2005 102: 10610-5. 13- Eldor R, Raz I. Lipotoxicity versus adipotoxicity—the deleterious effects of adipose tissue on beta cells in the pathogenesis of type 2 diabetes. Diabetes Res Clin Pract. 2006 74: S3-8. 14- Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine upregulated by insulin and obesity. Endocrinology. 2005 146: 1764-71. 15- So¨rhede Winzell M, Magnusson C, Ahre´n B. The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice. Regul Pept. 2005 131: 12-7. 16- Dumortier M, Brandou F, Perez-Martin A, Fedou C, Mercier J, Brun JF. Low intensity endurance exercise targeted for lipid oxidation improves body composition and insulin sensitivity in patients with the metabolic syndrome. Diabetes Metab. 2003 29: 509-18. 17- Heinonen MV, Purhonen AK, Miettinen P, et al. Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding. Regul Pept. 2005 130: 7-13. 18- Li L, Yang G, Li Q, et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes. 2006 114: 544-8. 19- Castan-Laurell I, Vitkova M, Daviaud D, et al. Effect of hypocaloric diet-induced weight loss in obese women on plasma apelin and adipose tissue expression of apelin and APJ. Eur J Endocrinol. 2008 158: 905-10. 20- Moreno-Navarrete JM, Catalán V, Ortega F, Gómez-Ambrosi J, Ricart W, Frühbeck G. Circulating omentin concentration increases after weight loss. Nutr Metabolism. 2010 7: 27. 21- Pan HY, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract. 2010 88: 29-33. 22- Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med. 2008 14: 741-51. 23- Conde J, Scotece M, Gomez R, et al. Adipokines: biofactors from white adipose tissue. A complex hub among inflammation, metabolism, and immunity. BioFactors. 2011 37: 413-420. 24- Audigier Y. Apelin receptor. UCSD - Nature Molecule Pages. Nature Publishing Group. 2006. 25- Lee DK, Cheng R, Nguyen T, et al. "Characterization of apelin, the ligand for the APJ receptor". J Neurochem. 2000 74: 34. 26- Xie H, Tang SY, Cui RR, et al. "Apelin and its receptor are expressed in human osteoblasts". Regul Pept. 2006 134: 118-25. 27- Kadoglou NP, Tsanikidis H, Kapelouzou A, Vrabas I, Vitta I, Karayannacos PE. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and gherlin levels in patients with type 2 diabetes mellitus. Meta Cli Expe. 2009 59: 373-79. 28- Mohebbi H, Rahmani nia F, Hedayati M, Saedi T. The effect of 8 weeks high intensity aerobic exercise on the Apelin and insulin resistance in older women with diabetes type 2. Exercise Physiology J. 2013: 20: 115-128. (Farsi) 29- Yang M, Yang G, Dong J, et al. Elevated plasma levels of chemerin in newly diagnosed type 2 diabetes mellitus with hypertension. J Investig Med. 2007 58: 883-886. 30- Saremi A, Asghari M, Ghorbani A. Effects of aerobic training on serum omentin-1 and cardiometabolic risk factors in overweight and obese men. Journal of Sports Sciences. 2010 28: 993-998.(Farsi) 31- Kang J. Nutrition and metabolism in sports, exercise and health. USA and Canada Routledge Publisher. 2012 262-9.

Full-Text [PDF 239 kb]   (158615 Downloads)    
Type of Study: Clinical Trials |
Received: 2015/06/2 | Accepted: 2015/06/2 | Published: 2015/06/2

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Advances in Medical and Biomedical Research

Designed & Developed by : Yektaweb